GlobeNewswire·Aug 17, 2026, 4:01 PM ET

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Zentalis Pharmaceuticals, Inc. closed an underwritten public offering of 26,450,000 common stock shares, including 3,450,000 shares from the full exercise of the underwriters' option.
Shares were sold at $3.50 per share, generating approximately $92.6 million in total gross proceeds before deductions.
All shares sold in the offering were issued by the Company.
Net proceeds will fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, pre-commercial activities, capital expenditures, working capital, and general corporate purposes.
TD Cowen, Guggenheim Securities, and Oppenheimer & Co. served as joint bookrunners, with H.C. Wainwright & Co. as a passive bookrunner and Rodman & Renshaw LLC as a manager.
The offering was executed under an effective shelf registration statement filed with the SEC on March 26, 2025, and effective April 4, 2025.
Final prospectus supplements are available via the SEC website or through direct contact with TD Securities, Guggenheim Securities, or Oppenheimer & Co.